	US 12,214,014 B2
	Methods for scar reduction by converting scar fibroblasts into adipocytes with hair follicle-derived signals
George Cotsarelis, Berwyn, PA (US); Christian F. Guerrero-Juarez, Redlands, CA (US); and Maksim Plikus, Irvine, CA (US)
Assigned to The Trustees of the University of Pennsylvania, Philadelphia, PA (US); and The Regents of the University of California, Oakland, CA (US)
Appl. No. 16/475,570
Filed by The Trustees of the University of Pennsylvania, Philadelphia, PA (US)
PCT Filed Jan. 3, 2018, PCT No. PCT/US2018/012266 § 371(c)(1), (2) Date Jul. 2, 2019, PCT Pub. No. WO2018/129101, PCT Pub. Date Jul. 12, 2018.
Claims priority of provisional application 62/442,321, filed on Jan. 4, 2017.
Prior Publication US 2020/0121760 A1, Apr. 23, 2020
Int. Cl. A61K 38/18 (2006.01); A61K 9/00 (2006.01); A61K 35/36 (2015.01); A61K 45/06 (2006.01); A61P 17/02 (2006.01)

CPC A61K 38/1875 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0021 (2013.01); A61K 35/36 (2013.01); A61K 45/06 (2013.01); A61P 17/02 (2018.01)]

10 Claims

1. A method for treating wound healing pathologies or for inhibiting or suppressing a fibrotic skin disorder in a subject having a wound healing pathology or fibrotic skin disorder, the method comprising the step of administering to the subject a composition consisting of therapeutically effective amount of a wild-type bone morphogenetic protein 2 (BMP2) polypeptide, or a wild-type bone morphogenetic protein 4 (BMP4) polypeptide, or a combination thereof.